Latest Health News

Race Oncology has activated its first clinical trial site in Hong Kong for the Phase 1 study of RC220 combined with doxorubicin in advanced solid tumours, marking a significant step in accelerating patient enrolment and broadening clinical data.

TALi Digital has successfully placed 446 million shares to close the shortfall from its recent entitlement offer, raising $446,000. The company also highlights its strategic acquisition of You Can Do It! Education, expanding its reach in digital health and social-emotional learning.

Biome Australia has partnered with Green Cross Health to launch its Activated Probiotics across New Zealand’s largest pharmacy network, marking a pivotal step in its international growth strategy.

Ryder Capital Limited reports a striking 12.75% preliminary gain in its investment portfolio for August 2025, lifting its pre-tax net tangible assets per share to $1.964 before dividend payout.

Pro Medicus’s U.S. subsidiary Visage Imaging has earned a critical Authority to Operate from the U.S. Department of Veterans’ Affairs, enabling its Visage 7 CloudPACS platform to transition to the Veterans Affairs Enterprise Cloud.

RLF AgTech has completed a $4.5 million placement by issuing over 90 million new shares, bolstering its capacity to advance sustainable crop nutrition solutions across Australia and Asia.

Lumos Diagnostics has secured a significant follow-on contract with Aptatek Biosciences to push forward the development of an innovative in-home monitoring device for Phenylketonuria (PKU), a rare genetic disorder. This next phase aims to bring the FDA Breakthrough Device-designated PheCheck™ closer to clinical trials and commercial readiness.

Clime Investment Management has reported a strong FY25 profit turnaround, posting $2.1 million pretax and amortisation profit and declaring a fully franked dividend. The company outlines ambitious growth and margin targets for FY26 amid strategic restructuring and technology investments.

Lumos Diagnostics, backed by BARDA, is set to begin a pivotal pediatric clinical study to extend the use of its rapid respiratory infection test, FebriDx, to children aged 2–12 in U.S. CLIA-waived settings, potentially unlocking a $1 billion market.

Pro-Pac Packaging is progressing a strategic review involving potential asset sales and liquidity support, with ASX trading suspension imminent pending financial disclosures.

Island Pharmaceuticals has formally requested a Type C meeting with the US FDA to discuss accelerating approval of its antiviral Galidesivir for Marburg virus using the Animal Rule pathway.

4DMedical Limited has secured FDA clearance for CT – VQ™, the first non-contrast CT-based ventilation-perfusion imaging technology, promising to transform lung diagnostics by replacing traditional nuclear scans.